SCHEMBL1892701

SCHEMBL1892701

CCc1nc2cc(NS(=O)(=O)c3ccc(F)cc3)ccc2n1CC(=O)O

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 8/20 0.55
PKM P14618 2/20 0.55
LMNA P02545 3/20 0.54
SMN1; SMN2 Q16637 4/20 0.52
HSD17B10 Q99714 2/20 0.52
F2 P00734 2/20 0.49
KDM4E B2RXH2 2/20 0.47
USP2 O75604 1/20 0.47
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47
TP53 P04637 1/20 0.47
TBXA2R P21731 1/20 0.46
TBXAS1 P24557 1/20 0.46
POLB P06746 1/20 0.46
APOBEC3A P31941 1/20 0.45
APOBEC3G Q9HC16 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1892270 0.92 LMNA (0.55) PTGDR2PKMLMNASMN1; SMN2HSD17B10
SCHEMBL1886986 0.90 LMNA (0.53) PTGDR2PKMLMNASMN1; SMN2HSD17B10
SCHEMBL1891240 0.89 LMNA (0.52) PTGDR2PKMLMNASMN1; SMN2HSD17B10
SCHEMBL1883833 0.89 PTGDR2 (0.52) PTGDR2PKMLMNASMN1; SMN2HSD17B10
SCHEMBL3831602 0.89 LMNA (0.51) PTGDR2PKMLMNASMN1; SMN2HSD17B10
SCHEMBL1888096 0.88 LMNA (0.52) PTGDR2PKMLMNASMN1; SMN2HSD17B10
SCHEMBL1883933 0.87 PKM (0.50) PTGDR2PKMLMNASMN1; SMN2HSD17B10
SCHEMBL1885814 0.85 PTGDR2 (0.54) PTGDR2PKMLMNASMN1; SMN2HSD17B10
SCHEMBL1889715 0.84 PTGDR2 (0.48) PTGDR2PKMLMNASMN1; SMN2HSD17B10
SCHEMBL1886704 0.84 PTGDR2 (0.51) PTGDR2PKMLMNASMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7732618-B2 Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof WYETH (US) 2010-06-08 US claimed
US-20110105573-A1 BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF WYETH 2011-05-05 US disclosed
US-20110105573-A1 BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF WYETH 2011-05-05 US disclosed
US-7732618-B2 Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof WYETH (US) 2010-06-08 US disclosed
US-7732618-B2 Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof WYETH (US) 2010-06-08 US disclosed
US-7732618-B2 Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof WYETH (US) 2010-06-08 US disclosed
US-20060106081-A1 Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof WYETH 2006-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106081-A1 Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof HRH2, TBXA2R, PTGDR2 PTGDR2 3/4885PKM 2215/4885LMNA 4735/4885
US-20110105573-A1 BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF HRH2, TBXA2R, PTGDR2 PTGDR2 3/4885PKM 2215/4885LMNA 4735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.